SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?


To: Henry Niman who wrote (851)11/24/1998 4:49:00 PM
From: Douglas Babbin  Respond to of 965
 
Merrill Lynch believes that CNTO's Remicade infusion reactions are a non-issue. They think the volatility in the shares may be due to the company over promising Remicade sales in 4Q, $30mil vs. ML's 4Q estimate of low $20mil